Verona Pharma plc (NASDAQ:VRNA) Q2 2024 Earnings Call Transcript
Operator: Welcome to Verona Pharma’s Second Quarter 2024 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode.
Verona Pharma Plc (VRNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 7,632,646 | $110,368,061 | +21% | 1.45% |
| 2. | Deep Track Capital David Kroin | 4,000,000 | $57,840,000 | +26% | 1.72% |
| 3. | Vivo Capital Albert Cha And Frank Kung | 3,549,758 | $51,329,501 | -2% | 4.74% |
| 4. | Maverick Capital Lee Ainslie | 3,092,807 | $44,721,989 | +75% | 0.84% |
| 5. | OrbiMed Advisors Samuel Isaly | 2,861,801 | $41,381,642 | -16% | 0.81% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.87 | 36,000 | Director | 880,643 | 2024-08-12 | Filing | |
| $1.84 | 33,736 | Director | 144,800 | 2023-11-20 | Filing | |
| $1.98 | 160,000 | Director | 844,643 | 2023-11-06 | Filing | |
| $1.31 | 4,800,000 | Large Shareholder | 55,911,648 | 2022-08-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.76 | 600,000 | Officer, Director | 15,250,704 | 2024-09-11 | Filing | |
| $3.76 | 600,000 | Officer | 14,339,688 | 2024-09-11 | Filing | |
| $3.25 | 8,216 | Officer, Director | 15,850,704 | 2024-08-13 | Filing | |
| $3.20 | 390,184 | Officer, Director | 15,858,920 | 2024-08-13 | Filing | |
| $3.13 | 1,600 | Officer, Director | 16,249,104 | 2024-08-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,108,563 | $111,024,890 | 7.39% | |
| 2. | 4,902,377 | $97,459,255 | 0% | |
| 3. | 3,783,994 | $75,225,800 | 0.01% | |
| 4. | 3,014,349 | $59,925,258 | 3.2% | |
| 5. | 2,493,530 | $49,571,376 | 0.12% |
News See All
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript
Operator: Hello, and welcome to Verona Pharma's First Quarter 2024 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode.
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript
Verona Pharma plc beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23.
11 Best Undervalued UK Stocks To Buy Now
In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now.
Verona Pharma plc (NASDAQ:VRNA) Q3 2023 Earnings Call Transcript
Operator: Welcome to Verona Pharma's Third Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode.
12 Best High Risk High Reward Stocks To Buy Now
In this piece, we will take a look at the 12 best high risk high reward stocks to buy now.
Verona Pharma plc (NASDAQ:VRNA) Q2 2023 Earnings Call Transcript
Operator: Welcome to Verona Pharma Second Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time all participants are in listen-only mode.
Verona Pharma plc (NASDAQ:VRNA) Q1 2023 Earnings Call Transcript
Operator: Good morning. Welcome to Verona Pharma's First Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a mode.
Verona Pharma plc (NASDAQ:VRNA) Q4 2022 Earnings Call Transcript
Operator: Welcome to Verona Pharma's, Fourth Quarter and Full Year 2022 Financial Results and Operating Highlights Conference Call. At this time all participants are in a listen-only mode.
Billionaire Hedge Funds
